Relentless Health Value

Darren is Chief Executive Officer at Aduro, Inc., a human performance company that delivers habit change programs that empower people and organizations to reach their full potential. He brings a unique outlook to the health care sector, combining his experience with the intricacies of the industry with potential he sees in groundbreaking technologies, human analytics and personalized well-being. With more than 15 years of expertise in demonstrated return on population health, Darren helps companies unlock the power of a happier, healthier, and higher-performing workforce. Prior to founding Aduro, Darren has served as Associate Doctor, Clinic Director and Chief Executive Officer of Clear Chiropractic, a collection of practices in the Puget Sound Area specializing in the Blair Chiropractic Technique. Darren received his Doctor of Chiropractic from Georgia's Life University and currently serves as Chairman of the Board at Clear Chiropractic. Darren spends an increasing amount of time developing new opportunities to bring his purpose-driven approach to the larger community with support for behavior health and nutritional lifestyles. When he's not igniting Aduro's culture at a Friday Fire all-company huddle, he can be found curating crowd-pleasing playlists or traversing down the slopes at his favorite mountain hideaway.

Gary is a disrupter and founder of OM Healthcare, Inc. a health care technology startup established in 2015. He has over 18 years of business development experience and over 13 years of executive-level hospital and health system strategy expertise. Gary is a thought leader in the new frontier of health care technology, innovation, and strategy. Over the years Mr. Frazier's leadership and expertise has been sought after for strategic business planning, financial planning, growth strategy, integrated delivery systems, program development, mergers and acquisitions, and physician alignment.

His roles have encompassed the rapid growth of Paladin Healthcare through hospital mergers and acquisitions, most notably a $170M acquisition of 2 Tenet hospitals in Philadelphia, PA. He served as a Principal for Vizient Consulting where he focused on physician/hospital alignment and hospital growth strategies for health systems throughout the United States. He was Vice President of Strategy and Business Development for a flagship 434-bed Dignity Health hospital in Central California where he was responsible for all strategy, growth, marketing, physician alignment, payer relations, and strategic partnerships. Before Dignity Health he managed all business development activities for hospital real estate transactions, expansions, and joint ventures in Arizona, California, and Nevada for Hammes Company Healthcare.

A native of Southern California, he earned an undergraduate degree from Cal State Dominguez Hills and an MBA from UC Irvine Paul Merage School of Business. He has served as a board member of the California Hospital Association Political Action Committee (CHPAC), the Bakersfield March of Dimes, and the American Heart Association in Central California, and was Chairman of the Bakersfield Museum of Art.

You can learn more at www.omhealthcare.com.

Gary is a disrupter and founder of OM Healthcare, Inc. a health care technology startup established in 2015. He has over 18 years of business development experience and over 13 years of executive-level hospital and health system strategy expertise. Gary is a thought leader in the new frontier of health care technology, innovation, and strategy. Over the years Mr. Frazier's leadership and expertise has been sought after for strategic business planning, financial planning, growth strategy, integrated delivery systems, program development, mergers and acquisitions, and physician alignment. His roles have encompassed the rapid growth of Paladin Healthcare through hospital mergers and acquisitions, most notably a $170M acquisition of 2 Tenet hospitals in Philadelphia, PA. He served as a Principal for Vizient Consulting where he focused on physician/hospital alignment and hospital growth strategies for health systems throughout the United States. He was Vice President of Strategy and Business Development for a flagship 434-bed Dignity Health hospital in Central California where he was responsible for all strategy, growth, marketing, physician alignment, payer relations, and strategic partnerships. Before Dignity Health he managed all business development activities for hospital real estate transactions, expansions, and joint ventures in Arizona, California, and Nevada for Hammes Company Healthcare. A native of Southern California, he earned an undergraduate degree from Cal State Dominguez Hills and an MBA from UC Irvine Paul Merage School of Business. He has served as a board member of the California Hospital Association Political Action Committee (CHPAC), the Bakersfield March of Dimes, and the American Heart Association in Central California, and was Chairman of the Bakersfield Museum of Art. You can learn more at www.omhealthcare.com.

Today I speak with my co-president Dave Dierk from Aventria Health Group about pharmaceutical companies collaborating with health innovators. There have been many articles written about the prospect of such collaborations, often authored it seems by people who haven’t actually been involved in such an arrangement. Sometimes I giggle at the delta between the rose-colored version and the no-filter version, but collaboration is the future and Pharma would be well served get good at it.

Stacey is co-president/CEO of Aventria Health Group, specializing in helping employer, pharmaceutical, device, and pharmacy clients by creating partnerships with other health care organizations. For 20 years, Stacey has innovated better-coordinated health solutions benefiting all stakeholders, and most of all, the patient. Dave is co-president/CEO of Aventria Health Group and president/CEO of Pinnacle Health Communications. He is a 27-year veteran of managed-markets marketing. After working in consumer marketing with AT&T and health care publishing with Elsevier, Dave made the move to medical advertising and communications at KI Lipton, Inc. Subsequently, he became a cofounder of Pinnacle. Dave is an accomplished strategist, providing innovative customer marketing, access, quality, and health intervention solutions for large clients and has directed the development of numerous industry-leading campaigns in primary care and specialty markets. He has supported clients in disease areas that include oncology (Bristol Myers Squibb [BMS], Novartis, Eisai), virology (BMS, Merck & Co.), pharmacy (American Pharmacists Association, Merck, Novartis), and blood disorders (Novo Nordisk), to name a few. Dave has helped more than 15 clients achieve top rankings in their respective categories. He is also an active member of the Pharmacy Quality Alliance. You can learn more about Aventria Health Group at aventriahealth.com or by emailing [email protected].

Americans spend a lot on prescription drugs, more per capita than any other country by far. Pharmacy spending used to be about 5% of total medical spend, but today it can be as high as 25%. Today I speak with Tim Thomas from Crystal Clear Rx about what we can do to ensure that we’re not overpaying for already pricey meds. As a case study, Tim talks about how Caterpillar is dealing with this trend.

Tim Thomas, RPh president, Crystal Clear Rx Mr. Thomas is a graduate of the University of South Carolina College of Pharmacy, and has 38 years' experience as a pharmacist. His management background includes residency training and being a Director of Pharmacy at both a hospital and an HMO. For the last 25 years Mr. Thomas has been involved in managed care pharmacy with expertise in formulary, benefit design, and creating value in the pharmacy benefit. He developed a PBM in the 1990's and has held senior positions within the PBM industry. In 2008 he created Crystal Clear Rx, a pharmacy benefit consulting and research firm that is singularly focused on helping clients realize better value from their pharmacy benefit by providing optics into the PBM contracting process, data analysis, and cost effective solutions. You can learn more at www.crystalclearrx.com.

Juan Pablo founded Babyscripts in 2014 with the vision that internet - enabled medical devices would transform the delivery of pregnancy care. Since 2014, Juan Pablo has been named a Healthcare Transformer by the Startup Health Academy in New York and a Wireless Lifechanger by CTIA for his work in detecting problems in pregnancy faster. Juan Pablo is also the architect of the first "Prenatal Care Moonshot" focused on eliminating preterm birth by 2027 through mobile/digital technology and Babyscripts has been named Champions of Change in Precision Medicine by Barack Obama and the White House.

Juan Pablo has raised $8.6 million in venture/angel financing for furthering his vision of a data centric model in prenatal care which includes the recent closure of a Series A of $5.5 million. He has orchestrated large partnerships with General Electric and their Healthymagination initiative and the March of Dimes specifically targeting the elimination of premature birth. He has also led the Babyscripts sales team, closing large hospital deals with more than 13 health systems around the country and successfully signing a co-development deal to build an at-risk product with Aurora Health Care in Wisconsin.

Juan Pablo is a frequent speaker on the future of health care. He has spoken at the mHealth Summit on "How to Demonstrate Value in Digital/Mobile Health," at the national HIMSS conference on "Establishing ROI and Forming Partnerships: Digital Health Dating," and at the Bio+Tech conference on "Collaborating for Patient Engagement." He has pitched and won Startup Competitions at SXSW at their Barracuda Bowl and the 1776 Healthcare Challenge Cup. He has also been invited to share his thoughts on podcasts and write op-ed articles on startup fundraising and the future of health care. He was recently interviewed by Medistrategy and wrote "3 Musts for Raising Your First Round" and "Why Disruption in Health IT is like a Tiramisu Cake."

Juan Pablo founded Babyscripts in 2014 with the vision that internet - enabled medical devices would transform the delivery of pregnancy care. Since 2014, Juan Pablo has been named a Healthcare Transformer by the Startup Health Academy in New York and a Wireless Lifechanger by CTIA for his work in detecting problems in pregnancy faster. Juan Pablo is also the architect of the first "Prenatal Care Moonshot" focused on eliminating preterm birth by 2027 through mobile/digital technology and Babyscripts has been named Champions of Change in Precision Medicine by Barack Obama and the White House. Juan Pablo has raised $8.6 million in venture/angel financing for furthering his vision of a data centric model in prenatal care which includes the recent closure of a Series A of $5.5 million. He has orchestrated large partnerships with General Electric and their Healthymagination initiative and the March of Dimes specifically targeting the elimination of premature birth. He has also led the Babyscripts sales team, closing large hospital deals with more than 13 health systems around the country and successfully signing a co-development deal to build an at-risk product with Aurora Health Care in Wisconsin. Juan Pablo is a frequent speaker on the future of health care. He has spoken at the mHealth Summit on "How to Demonstrate Value in Digital/Mobile Health," at the national HIMSS conference on "Establishing ROI and Forming Partnerships: Digital Health Dating," and at the Bio+Tech conference on "Collaborating for Patient Engagement." He has pitched and won Startup Competitions at SXSW at their Barracuda Bowl and the 1776 Healthcare Challenge Cup. He has also been invited to share his thoughts on podcasts and write op-ed articles on startup fundraising and the future of health care. He was recently interviewed by Medistrategy and wrote "3 Musts for Raising Your First Round" and "Why Disruption in Health IT is like a Tiramisu Cake."

Jennifer E. Miller, PhD, is an Assistant Professor at the NYU School of Medicine and President of the nonprofit, Bioethics International. She is also the Creator of the Good Pharma Scorecard, an index that ranks all new drugs and large pharmaceutical companies on their ethics and public health performance to help recognize good practices in companies, improve trustworthiness, and incentivize change where needed.  Prior to joining NYU, Dr. Miller was based at Harvard University.

Dr. Miller currently serves on NYU’s Pharmacy and Therapeutics Committee and Stem Cell Research Oversight IRB, as well as the J&J-NYU Compassionate-Use Advisory Committee (monitor). Previously, she served on the Center for Disease Control and Prevention’s (CDC) Task Force for Pediatric Emergency Mass Critical Care, the American Medical Association’s (AMA) Advanced Disaster Life Support Education Consortium, as a consultant to the United Nations Economic and Social Council, and on the PCORI-NIH Collaboratory.

A prolific writer, Dr. Miller has authored over 35 articles in publications including Nature Medicine and Health Affairs. She was a Fox News pundit from 2009 to 2012 and remains a news commentator, frequently featured on CBS news, Wall Street Journal, Washington Post, Bloomberg News, Forbes, and NPR.

Dr. Miller’s current work explores the ethics and governance of new drugs that are researched, developed, marketed, priced, and made accessible to patients globally. She also specializes in the ethics of data sharing.

00:00 EP148: Jennifer E. Miller, PhD, Bioethics International and Creator of the Good Pharma Scorecard. 01:00 The Good Pharma Scorecard rankings for 2017. 01:40 Two 100% transparent pharma companies. 02:20 Two stats that prove that Pharma companies are improving. 03:00 Industry improvements on patient trials. 03:25 Ninety-six percent of all patient trials are available to the public. 03:45 Where there wasn’t a significant improvement in disclosure in pharma.